Celgene receives European Commission Approval for Lenalidomide (Revlimid (R)) and Pomalidomide (Imnovid (R))-based Triplet-Combination Therapies for the Treatment of Patients with multiple Myeloma

首页> 外文期刊>Oncology research and treatment. >Celgene receives European Commission Approval for Lenalidomide (Revlimid (R)) and Pomalidomide (Imnovid (R))-based Triplet-Combination Therapies for the Treatment of Patients with multiple Myeloma

【24h】

Celgene receives European Commission Approval for Lenalidomide (Revlimid (R)) and Pomalidomide (Imnovid (R))-based Triplet-Combination Therapies for the Treatment of Patients with multiple Myeloma

机译：Celgene接受欧洲委员会对Lenalidomide（Revlimid（R））和氟三种（IMNovid（r））的三重态组合疗法治疗多发性骨髓瘤的疗效

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2019年第9期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Celgene receives European Commission Approval for Lenalidomide (Revlimid (R)) and Pomalidomide (Imnovid (R))-based Triplet-Combination Therapies for the Treatment of Patients with multiple Myeloma [J] . Oncology research and treatment. . 2019,第9期

机译：Celgene接受欧洲委员会对Lenalidomide（Revlimid（R））和氟三种（IMNovid（r））的三重态组合疗法治疗多发性骨髓瘤的疗效
2. Treatment of the multiple Myeloma in Adults European Commission grants Approval for Elotuzumab (Empliciti((R))) in Combination with Lenalidomide and Dexamethasone [J] . Oncology research and treatment. . 2016,第9期

机译：成年人多发性骨髓瘤的治疗欧洲委员会批准与来那度胺和地塞米松联用的依洛珠单抗（Empliciti（R））
3. Hope for intensively pretreated myeloma patients: Pomalidomide (Imnovid?) is newly approved for multiple myeloma [J] . ArnheimK. Onkologie . 2013,第10期

机译：强烈接受预处理的骨髓瘤患者的希望：Pomalidomide（Imnovid？）被新批准用于多发性骨髓瘤
4. A feasibility study of IMRT for the treatment of cervical cancer patients unable to receive intracavitary brachytherapy [C] . Roeske, J.C., Lujan, Engineering in Medicine and Biology Society, 2000. Proceedings of the 22nd Annual International Conference of the IEEE . 2000

机译：IMRT治疗无法接受腔内近距离放射治疗的宫颈癌患者的可行性研究
5. Existential Factors Influencing End-of-Life Treatment Decision Making: The Role of Death Anxiety And Meaning In Life in Choosing to Receive Destination Therapy Left Ventricular Assist Device in Advanced Heart Failure Patients [D] . Clement, Lacey Renee. 2018

机译：影响生命结束治疗决策的存在因素：在先进心力衰竭患者中选择接受目的地疗法左心室辅助装置的生活中死亡焦虑和意义的作用
6. Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma [O] . Lisa A. Raedler 2016

机译：Revlimid（来那度胺）现在被FDA批准为多发性骨髓瘤患者的一线疗法
7. Pomalidomide (Pomalidomide Celgene/Pomalyst®) for the ≥ 3rd-line therapy of patients with relapsed and refractory multiple myeloma [O] . Nachtnebel A. 2013

机译：Pomalidomide（Pomalidomide Celgene /Pomalyst®）用于复发性和难治性多发性骨髓瘤患者的≥3线治疗

Celgene receives European Commission Approval for Lenalidomide (Revlimid (R)) and Pomalidomide (Imnovid (R))-based Triplet-Combination Therapies for the Treatment of Patients with multiple Myeloma

著录项

相似文献

相关主题

期刊订阅